Vertex Pharma (VRTX) Misses Q4 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Vertex Reports Fourth Quarter and Full Year 2024 Financial Results
February 10, 2025 4:01 PM ESTFull year product revenue of $11.02 billion, a 12% increase compared to full year 2023
Company provides full year 2025 total revenue guidance of $11.75 to $12.0 billion
ALYFTREK approved in the U.S. for patients ages 6+ with cystic fibrosis; JOURNAVX approved in the U.S. for moderate-to-severe acute pain
Diverse late-stage clinical pipeline accelerates with four programs in pivotal development
Stuart Arbuckle, Chief Operating Officer, announces intent to retire July 1, 2025; as part of planned transition, Charlie Wagner, Chief Financial Officer, to assume additional role of Chief Operating... More
